We have already shown that our newly developed CYP2E1 inhibitor 12-imidazolyl-1-dodecanol (I-ol) was therapeutically effective against alcoholic and nonalcoholic steatohepatitis. Here, CYP2E1 is linked to metabolic dysfunction-associated steatohepatitis.